^
Association details:
| Biomarker: | PIM1 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Imbruvica (ibrutinib) (BTK inhibitor) + AZD1208 (PIM inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression
Published date:
08/26/2020
Excerpt:
105 mutational sites of PIM1 were seen in 36 patients...BCL2 inhibitor venetoclax was added to enhance the effectiveness of ibrutinib and AZD 1208...Encouragingly, venetoclax did show a prominent synergistic effect when combined with ibrutinib and AZD 1208, even though it alone did not produce obvious apoptosis.
Secondary therapy:
venetoclax + ibrutinib
DOI:
10.1186/s40364-020-00214-3
